Rufinamide (BioDeep_00000183056)

Main id: BioDeep_00000015050

 

human metabolite blood metabolite


代谢物信息卡片


1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide

化学式: C10H8F2N4O (238.06661419999998)
中文名称: 卢非酰胺
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F
InChI: InChI=1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

描述信息

D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AF - Carboxamide derivatives
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
D049990 - Membrane Transport Modulators

同义名列表

5 个代谢物同义名

1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide; 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide; Rufinamide; Inovelon; Banzel



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Saurabh B Ganorkar, Suraj R Chaudhari, Preeti S Bobade, Sagar H Pawar, Atul A Shirkhedkar. HPLC-PDA identification and resolution of rufinamide forced degradation impurities: A congregated chemometric expedite optimization coupled with factorials and desirability. Biomedical chromatography : BMC. 2022 May; 36(5):e5345. doi: 10.1002/bmc.5345. [PMID: 35062045]
  • J J García-Peñas, A Gil Nagel-Rein, R Sánchez-Carpintero, V Villanueva-Haba. Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain. Revista de neurologia. 2021 09; 73(S01):S1-S8. doi: 10.33588/rn.73s01.2021250. [PMID: 34486101]
  • Sonia T Hassib, Hanaa M A Hashem, Marianne A Mahrouse, Eman A Mostafa. Development and Bio-Analytical Validation of Chromatographic Determination Method of Rufinamide in Presence of its Metabolite in Human Plasma. Journal of chromatographic science. 2021 Apr; 59(5):458-464. doi: 10.1093/chromsci/bmaa142. [PMID: 33506266]
  • Valentina Franco, Giuliana Gatti, Iolanda Mazzucchelli, Roberto Marchiselli, Cinzia Fattore, Paola Rota, Carlo Andrea Galimberti, Giuseppe Capovilla, Francesca Beccaria, Valentina De Giorgis, Cecilie Johannessen Landmark, Emilio Perucca. Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. Epilepsia. 2020 07; 61(7):e79-e84. doi: 10.1111/epi.16584. [PMID: 32562438]
  • Sara Meirinho, Márcio Rodrigues, Ana Fortuna, Amílcar Falcão, Gilberto Alves. Novel bioanalytical method for the quantification of rufinamide in mouse plasma and tissues using HPLC-UV: A tool to support pharmacokinetic studies. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2019 Aug; 1124(?):340-348. doi: 10.1016/j.jchromb.2019.06.021. [PMID: 31279290]
  • Avantika V Dalvi, Chandra Teja Uppuluri, Ekta Prasanthi Bommireddy, Punna Rao Ravi. Design of experiments-based RP - HPLC bioanalytical method development for estimation of Rufinamide in rat plasma and brain and its application in pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2018 Dec; 1102-1103(?):74-82. doi: 10.1016/j.jchromb.2018.10.014. [PMID: 30380466]
  • Bai Hui Chen, Ji Hyeon Ahn, Joon Ha Park, Minah Song, Hyunjung Kim, Tae-Kyeong Lee, Jae Chul Lee, Young-Myeong Kim, In Koo Hwang, Dae Won Kim, Choong-Hyun Lee, Bing Chun Yan, Il Jun Kang, Moo-Ho Won. Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB. Chemico-biological interactions. 2018 Apr; 286(?):71-77. doi: 10.1016/j.cbi.2018.03.007. [PMID: 29548728]
  • Tyler E Gaston, E Martina Bebin, Gary R Cutter, Yuliang Liu, Jerzy P Szaflarski. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017 09; 58(9):1586-1592. doi: 10.1111/epi.13852. [PMID: 28782097]
  • Sanjeev Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, Omar Olhaye, Carlos Perdomo, Francesco Bibbiani. Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data. Seizure. 2017 Apr; 47(?):25-33. doi: 10.1016/j.seizure.2017.02.008. [PMID: 28284045]
  • Mingzhen Xu, Yang Ni, Ying Zhou, Xiaomeng He, Huqun Li, Hui Chen, Weiyong Li. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects. European journal of drug metabolism and pharmacokinetics. 2016 Oct; 41(5):541-8. doi: 10.1007/s13318-015-0291-4. [PMID: 26294172]
  • Alexis Arzimanoglou, Jose A Ferreira, Andrew Satlin, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Ziad Hussein, Dinesh Kumar, Shobha Dhadda, Francesco Bibbiani. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2016 May; 20(3):393-402. doi: 10.1016/j.ejpn.2015.12.015. [PMID: 26805435]
  • Zsolt Gáll, Szende Vancea, Tibor Szilágyi, Orsolya Gáll, Melinda Kolcsár. Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2015 Feb; 68(?):106-13. doi: 10.1016/j.ejps.2014.12.012. [PMID: 25530452]
  • Yoko Ohtsuka, Harumi Yoshinaga, Yukiyoshi Shirasaka, Rumiko Takayama, Hiroki Takano, Kuniaki Iyoda. Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy research. 2014 Nov; 108(9):1627-36. doi: 10.1016/j.eplepsyres.2014.08.019. [PMID: 25219353]
  • Zsolt Gáll, Szende Vancea, Maria T Dogaru, Tibor Szilágyi. Liquid chromatography-mass spectrometric determination of rufinamide in low volume plasma samples. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2013 Dec; 940(?):42-6. doi: 10.1016/j.jchromb.2013.07.014. [PMID: 24140655]
  • Giancarlo la Marca, Anna Rosati, Melania Falchi, Sabrina Malvagia, Maria Luisa Della Bona, Simona Pellacani, Renzo Guerrini. A pharmacokinetic study and correlation with clinical response of rufinamide in infants with epileptic encephalopathies. Pharmacology. 2013; 91(5-6):275-80. doi: 10.1159/000350392. [PMID: 23711937]
  • H M Wright, A V Chen, S E Martinez, N M Davies. Pharmacokinetics of oral rufinamide in dogs. Journal of veterinary pharmacology and therapeutics. 2012 Dec; 35(6):529-33. doi: 10.1111/j.1365-2885.2011.01353.x. [PMID: 22132708]
  • Maria G Dahlin, Inger Ohman. Rufinamide in children with refractory epilepsy: pharmacokinetics, efficacy, and safety. Neuropediatrics. 2012 Oct; 43(5):264-70. doi: 10.1055/s-0032-1324403. [PMID: 22941776]
  • Danièle Bentué-Ferrer, Olivier Tribut, Marie-Clémence Verdier. [Therapeutic drug monitoring of rufinamide]. Therapie. 2012 Mar; 67(2):161-5. doi: 10.2515/therapie/2012013. [PMID: 22850104]
  • Iolanda Mazzucchelli, Manuela Rapetti, Cinzia Fattore, Valentina Franco, Giuliana Gatti, Emilio Perucca. Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. Analytical and bioanalytical chemistry. 2011 Aug; 401(3):1013-21. doi: 10.1007/s00216-011-5126-9. [PMID: 21643856]
  • Theodor W May, Rainer Boor, Bernhard Rambeck, Uwe Jürgens, Elisabeth Korn-Merker, Christian Brandt. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication. Therapeutic drug monitoring. 2011 Apr; 33(2):214-21. doi: 10.1097/ftd.0b013e31820fa9ad. [PMID: 21383651]
  • Heather Ann Wier, Ana Cerna, Tsz-Yin So. Rufinamide for pediatric patients with Lennox-Gastaut syndrome: a comprehensive overview. Paediatric drugs. 2011 Apr; 13(2):97-106. doi: 10.2165/11586920-000000000-00000. [PMID: 21351809]
  • C von Stülpnagel, M Leichsenring, A Müller, M Staudt, G Kluger. Refractory focal epilepsy in a patient with methylmalonic aciduria: case report on positive and long-lasting effect of rufinamide. Neuropediatrics. 2011 Feb; 42(2):71-3. doi: 10.1055/s-0031-1277177. [PMID: 21547865]
  • Giancarlo la Marca, Sabrina Malvagia, Luca Filippi, Marzia Innocenti, Anna Rosati, Melania Falchi, Simona Pellacani, Gloriano Moneti, Renzo Guerrini. Rapid assay of rufinamide in dried blood spots by a new liquid chromatography-tandem mass spectrometric method. Journal of pharmaceutical and biomedical analysis. 2011 Jan; 54(1):192-7. doi: 10.1016/j.jpba.2010.07.015. [PMID: 20708364]
  • David John Critchley, Jagadeesh Aluri, Peter Boyd, Matthew Whayman, Milind Narurkar, Hugh Delargy, Francesco Bibbiani. Bioavailability of three rufinamide oral suspensions compared with the marketed 400-mg tablet formulation: results from a randomized-sequence, open-label, four-period, four-sequence crossover study in healthy subjects. Clinical therapeutics. 2011 Jan; 33(1):146-57. doi: 10.1016/j.clinthera.2011.01.016. [PMID: 21397780]
  • Muhannad R M Salih, Mohd Baidi Bahari, Arwa Y Abd. Selected pharmacokinetic issues of the use of antiepileptic drugs and parenteral nutrition in critically ill patients. Nutrition journal. 2010 Dec; 9(?):71. doi: 10.1186/1475-2891-9-71. [PMID: 21194458]
  • Svein I Johannessen, Cecilie Johannessen Landmark. Antiepileptic drug interactions - principles and clinical implications. Current neuropharmacology. 2010 Sep; 8(3):254-67. doi: 10.2174/157015910792246254. [PMID: 21358975]
  • Christopher S Wisniewski. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome. The Annals of pharmacotherapy. 2010 Apr; 44(4):658-67. doi: 10.1345/aph.1m679. [PMID: 20233912]
  • Manuela Contin, Susan Mohamed, Carmina Candela, Fiorenzo Albani, Roberto Riva, Agostino Baruzzi. Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2010 Feb; 878(3-4):461-5. doi: 10.1016/j.jchromb.2009.11.039. [PMID: 20005185]
  • Emilio Perucca, James Cloyd, David Critchley, Eliane Fuseau. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008 Jul; 49(7):1123-41. doi: 10.1111/j.1528-1167.2008.01665.x. [PMID: 18503564]
  • M C Rouan, C Buffet, L Masson, F Marfil, H Humbert, G Maurer. Practice of solid-phase extraction and protein precipitation in the 96-well format combined with high-performance liquid chromatography-ultraviolet detection for the analysis of drugs in plasma and brain. Journal of chromatography. B, Biomedical sciences and applications. 2001 Apr; 754(1):45-55. doi: 10.1016/s0378-4347(00)00576-4. [PMID: 11318426]
  • S Pålhagen, R Canger, O Henriksen, J A van Parys, M E Rivière, M A Karolchyk. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy research. 2001 Feb; 43(2):115-24. doi: 10.1016/s0920-1211(00)00185-6. [PMID: 11164700]
  • J M Cardot, J B Lecaillon, C Czendlik, J Godbillon. The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharmaceutics & drug disposition. 1998 May; 19(4):259-62. doi: 10.1002/(sici)1099-081x(199805)19:4<259::aid-bdd98>3.0.co;2-v. [PMID: 9604126]
  • W K Cheung, F Kianifard, A Wong, J Mathieu, T Cook, V John, E Redalieu, K Chan. Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg tablets and 400-mg suspension. Pharmaceutical research. 1995 Dec; 12(12):1878-82. doi: 10.1023/a:1016275402723. [PMID: 8786960]
  • M C Rouan, C Souppart, L Alif, D Moes, J B Lecaillon, J Godbillon. Automated analysis of a novel anti-epileptic compound, CGP 33,101, and its metabolite, CGP 47,292, in body fluids by high-performance liquid chromatography and liquid-solid extraction. Journal of chromatography. B, Biomedical applications. 1995 May; 667(2):307-13. doi: 10.1016/0378-4347(95)00026-f. [PMID: 7663704]
  • L A Brunner, M L Powell. An automated method for the determination of a new potential antiepileptic agent (CGP 33101) in human plasma using high performance liquid chromatography. Biomedical chromatography : BMC. 1992 Nov; 6(6):278-82. doi: 10.1002/bmc.1130060606. [PMID: 1286284]